American Journal of Neuroradiology, Vol 19, Issue 3 541-546, Copyright © 1998 by American Society of Neuroradiology
ARTICLES |
Usefulness of contrast material in MR of patients with neurofibromatosis type 1
C Bonawitz, M Castillo, CT Chin, SK Mukherji and AJ Barkovich
Department of Radiology, University of North Carolina, Chapel Hill 27599, USA.
PURPOSE: Our objective was to determine the usefulness of routine administration of contrast material in brain MR imaging for the evaluation of areas of probable myelin vacuolization and neoplasms in patients with neurofibromatosis type 1 (NF-1). METHODS: We retrospectively reviewed 112 consecutive contrast-enhanced brain MR studies obtained over a period of 7 years in 109 symptomatic and asymptomatic patients compiled from two institutional NF-1 data bases. MR studies were analyzed for areas of probable myelin vacuolization, with attention to degree of enhancement and its impact on lesion detection and characterization. Usefulness of contrast material was graded as 0 = not useful, 1+ = somewhat useful, and 2+ = useful. RESULTS: Of 112 studies, 45% (n = 49) were normal. In the remaining 63 studies, 88 regions of probable myelin vacuolization and 52 tumors were identified. Enhancement was not observed in any regions of probable myelin vacuolization. Enhancement was present in 31% of tumors, and, of these, was found to be useful in 44%, somewhat useful in 12%, and not useful in 44%. For enhancing tumors, contrast agent was useful for lesion detection in 19% and for lesion characterization in 25%. CONCLUSION: Contrast administration is useful in baseline MR studies to maximize tumor detection and characterization, to add confidence to the diagnosis of benign probable myelin vacuolization, and to document stability of neoplasms on follow-up examinations.
This article has been cited by other articles:
 |
|
 |
|
  L. Margari, A. Presicci, P. Ventura, S. M. Bacca, G. Iliceto, N. Medicamento, M. Buttiglione, and T. Perniola Clinical and Instrumental (Magnetic Resonance Imaging [MRI] and Multimodal Evoked Potentials) Follow-Up of Brain Lesions in Three Young Patients With Neurofibromatosis 1 J Child Neurol, December 1, 2006; 21(12): 1085 - 1090. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-S. Guillamo, A. Creange, C. Kalifa, J. Grill, D. Rodriguez, F. Doz, S. Barbarot, M. Zerah, M. Sanson, S. Bastuji-Garin, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients Brain, January 1, 2002; 126(1): 152 - 160. [Abstract] [Full Text] [PDF]
|
|